144 related articles for article (PubMed ID: 33241594)
21. [Current aspects of prostate cancer screening].
Jalón Monzón A; Escaf Barmadah S; Viña Alonso LM; Jalón Monzón M
Semergen; 2017; 43(5):387-393. PubMed ID: 27562331
[TBL] [Abstract][Full Text] [Related]
22. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
23. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
Hugosson J; Aus G; Becker C; Carlsson S; Eriksson H; Lilja H; Lodding P; Tibblin G
BJU Int; 2000 Jun; 85(9):1078-84. PubMed ID: 10848699
[TBL] [Abstract][Full Text] [Related]
24. Personalized strategies in population screening for prostate cancer.
Remmers S; Roobol MJ
Int J Cancer; 2020 Dec; 147(11):2977-2987. PubMed ID: 32394421
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen testing and prostate cancer screening.
Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
[TBL] [Abstract][Full Text] [Related]
26. [Intelligent early prostate cancer detection in 2021: more benefit than harm].
Westhoff N; von Hardenberg J; Michel MS
Urologe A; 2021 May; 60(5):602-609. PubMed ID: 33881554
[TBL] [Abstract][Full Text] [Related]
27. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
28. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
29. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
BJU Int; 2017 Apr; 119(4):560-566. PubMed ID: 27222299
[TBL] [Abstract][Full Text] [Related]
30. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
31. PSA measurement and prostate cancer--overdiagnosis and overtreatment?
Breidablik HJ; Meland E; Aakre KM; Førde OH
Tidsskr Nor Laegeforen; 2013 Sep; 133(16):1711-6. PubMed ID: 24005707
[TBL] [Abstract][Full Text] [Related]
32. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
33. The prostate cancer pseudo-epidemic.
Adami HO
Acta Oncol; 2010 Apr; 49(3):298-304. PubMed ID: 20397765
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Duffy MJ
Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
[TBL] [Abstract][Full Text] [Related]
35. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
36. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
37. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
38. Balancing the harms and benefits of early detection of prostate cancer.
van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A
Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233
[TBL] [Abstract][Full Text] [Related]
39. Screening, early detection, and treatment of prostate cancer: a European view.
Schröder FH
Urology; 1995 Sep; 46(3 Suppl A):62-70. PubMed ID: 7653022
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
